Becoming a Clinical Trialist

Related

• 

  Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials

  Charles C Wykoff, MD, PhD, FASRS

  Updates from the Field

  2022

• 

  Episode 1: Review of the Clarity Study with Dr. Amin Kherani

  Keyvan Koushan, MD, FRCSC

  Member Podcasts

  2017

• 

  Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial

  Jason Hsu, MD

  Annual Meeting Talks

  2021